4-Hydroxy-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline (PI-OH) (1a) and its derivatives form a new class of compounds which possess norepinephrine (NE) potentiating activity. As a new series of compounds, 1-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines (2a-f) were synthesized by the intramolecular Barbier reaction of N-[2-(2-iodophenyl)ethyl]phenacylamines (6a-f) with n-BuLi as a key reaction step. The potentiating activities of the benzazepines 2a-f on the contraction of rat anococcygeus muscle induced by NE were tested. Among the compounds tested in this study, compound 2a showed moderate potentiating activity (the activity ratio was 7.3-fold at 3؋10 ؊5 M).
Amine reuptake inhibitors have been developed as antidepressants. Tricyclic antidepressants such as desipramine prevent the neuronal reuptake of either norepinephrine (NE) or serotonin (5-HT). 1) In the past decade a number of nontricyclic antidepressants, including selective serotonin reuptake inhibitors (SSRI) as well as 5-HT and NE reuptake inhibitors (SNRI) such as fluvoxamine and milnacipran, which have diminished cardiovascular and anticholinergic liability, have been developed.
2) Atomoxetine, a selective inhibitor of NE reuptake, has recently attracted much interest in the treatment of attention deficit hyperactivity disorder (ADHD)
3) (Fig. 1 ). We have reported on the synthesis of 4-hydroxy-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline (PI-OH) (1a) 4, 5) and the strong NE potentiating activity of PI-OH (1a) was found to be due to inhibition of NE reuptake. The potency of PI-OH (1a) was greater than that of the tricyclic antidepressant desipramine. 6) We have also studied the structure-activity relationships of the PI-OH (1a) analogues and have identified the importance of the 2-phenylethanolamine moiety of PI-OH for NE potentiation. 7, 8) In addition, we have evaluated the substitution effects on the 4-phenyl group of PI-OH (1a) and have found that the activity of 1b bearing a chlorine atom at the para position of the 4-phenyl group was greater than that of PI-OH (1a), however, the activity of the meta chloro analogue 1c was less potent than that of PI-OH (1a). 7) From these findings, 1-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (2a) and the derivatives 2b-f which have a halogen atom on the 1-phenyl group of 2a are interesting as new NE potentiators. This paper describes the synthesis and NE potentiating activity of the 3-benzazepines 2a-f.
In previous papers, we reported on the convenient synthesis of PI-OH (1a) and its related compounds, 9) 3-hydroxy-3-phenylindoles, 10 ) and 1,2-diphenyl-1-hydroxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (3) 11) by the intramolecular Barbier reaction of the corresponding N-benzyl-and N-phenylphenacylamines, and N- [2-(2-iodophenyl) ethyl]-aphenylphenacylamines with n-butyllithium (n-C 4 H 9 Li), both in good yields.
Thus, we synthesized 1-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines (2a-f) by the intramolecular Barbier reaction of N- [2-(2-iodophenyl) ethyl]-N-methylphenacylamines (6a-f) as a key reaction step as shown in Chart 1. The condensation of N-methyl-2-(2-iodophenyl)ethylamine (4) with phenacyl bromides (5a-f) 7) gave the phenacylamines 6a-f. Intramolecular cyclization of 6a-f with nBuLi afforded the 3-benzazepines 2a-f in a yield of 14.7-38.7% along with the reduced compounds 7a-f of the starting materials 6a-f in a yield of 18.4-49.3%, respectively. Although compound 2a was obtained in a moderate yield (38.7%) with the reduced compound 7a in a yield of 18.4%, the halogenated compounds 2b-f were produced in low yields (14.7-23.6%) with the reduced compounds 7b-f in The potentiating effects of the 3-benzazepines 2a-f as well as PI-OH (1a) on the contraction of rat anococcygeus muscle induced by NE were determined by the methods reported in our previous papers. [6] [7] [8] The results of these experiments are shown in Table 1 . Of the compounds prepared in this study, compound 2a had no substituent on the 4-phenyl group and had moderate potentiating activity (activity ratio was 7.3-fold at 3ϫ10
4-(4-Chlorophenyl)isoquinoline 1b showed greater potentiating activity 7) than PI-OH (1a), whereas 1-(4-chlorophenyl)-3-benzazepine 2b in addition to 2d-f showed no activity, even though 1-(3-chlorophenyl) derivative 2c revealed almost the same activity as 2a. These results indicated that 4-hydroxy-4-phenylisoqinoline with an ethanolamine moiety and a six-membered ring such as PI-OH (1a) was the preferred structure for the inhibition of NE reuptake rather than the 1-hydroxy-1-phenyl-3-benzazepines 2a-f constructed with a seven-membered ring expanded from the isoquinoline structure of PI-OH (1a).
Experimental
General All melting points are given as uncorrected values. IR spectra were obtained with a Perkin-Elmer 1720 infrared fourier transform spectrometer. High-resolution mass (HR-MS) spectra were recorded on a JEOL JMS-D 300 spectrometer.
1 H-NMR spectra were recorded on a JEOL JNM-FX 200 spectrometer with tetramethylsilane as a standard.
N-[2-(2-Iodophenyl)ethyl]-N-methylphenacylamine (6a)
A solution of N-methyl-2-(2-iodophenyl)ethylamine (4) (1.228 g, 4.70 mmol), phenacyl bromide (5a) (0.468 g, 2.35 mmol) in dioxane (10 ml) was stirred at room temperature for 5 h. The mixture was filtered and the filtrate was evaporated to give an oil (1.124 g). This was subjected to column chromatography on SiO 2 with CH 2 Cl 2 -n-hexane-AcOEt (3 : 3 : 1) to afford 6a as a pale brown oil (0.622 g, 69.5%). 
3-Chloro-N-[2-(2-iodophenyl)ethyl]-N-methylphenacylamine (6c)
Compound 4 (1.985 g, 7.60 mmol) was reacted with 5c (0.801 g, 3.43 mmol) in dioxane (20 ml) under reflux for 2 h to give a crude oil (1.777 g). This was subjected to column chromatography on SiO 2 with CH 2 Cl 2 -AcOEt (10 : 1) to afford 6c as a pale brown oil (1.108 g, 78.1%). 
4-Fluoro-N-[2-(2-iodophenyl)ethyl]-N-methylphenacylamine (6d)
Compound 4 (5.741 g, 22.0 mmol) was reacted with 5d (2.377 g, 11.0 mmol) in dioxane (50 ml) under reflux for 2 h to give a crude oil (5.268 g). This was subjected to column chromatography on SiO 2 with CH 2 Cl 2 -AcOEt (7 : 1) to afford 6d as a pale yellow oil (2.462 g, 28.2%). 1 
4-Bromo-N-[2-(2-iodophenyl)ethyl]-N-methylphenacylamine (6e)
Compound 4 (5.335 g, 20.4 mmol) was reacted with 5e (2.860 g, 10.3 mmol) in dioxane (60 ml) under reflux for 2 h to give a crude oil (7.519 g). This was subjected to column chromatography on SiO 2 with CH 2 Cl 2 -AcOEt (10 : 1) to afford 6e as a yellow oil (1.981 g, 21.2%). 1-Hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine (2a) n-BuLi (0.42 ml of 1.6 M solution in n-hexane, 0.67 mmol) was added to a solution of 6a (0.195 g, 0.51 mmol) in dry tetrahydrofuran (THF) (5 ml) under N 2 at Ϫ78°C. The mixture was stirred for 10 min at Ϫ78°C and then at room temperature for 10 min. H 2 O (20 ml) was added and the mixture was extracted with ether (20 mlϫ4). The extract was dried over MgSO 4 and evaporated to give a brown oil (0.142 g). This was subjected to column chromatography on SiO 2 with CH 2 Cl 2 -AcOEt (1 : 1). The first fraction gave 7a as a pale brown oil (0.0235 g, 18.4% The 3-benzazepines 2b-f were prepared in the same way as 2a. Chlorophenyl)-1-hydroxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (2b) Compound 6b (1.027 g, 2. 48 mmol) was treated with nBuLi (2.5 ml of 1.6 M solution in n-hexane, 4.0 mmol) in dry THF (10 ml). The crude oily product (0.786 g) was subjected to column chromatography on SiO 2 with CH 2 Cl 2 -AcOEt (7 : 1). The first fraction gave 7b as a pale yellow oil (0.257 g, 36.1% 
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1-(3-Chlorophenyl)-1-hydroxy-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (2c)
Compound 6c (1.077 g, 2.60 mmol) was treated with nBuLi (2.0 ml of 1.6 M solution in n-hexane, 3.2 mmol) in dry THF (6 ml). The crude oily product (0.892 g) was subjected to column chromatography on SiO 2 with CH 2 Cl 2 -AcOEt (3 : 2). The first fraction gave 7c as a pale yellow oil (0.263 g, 35.1%). Pharmacology Detailed methods used for the evaluation of compounds 2a-f were reported in previous papers 7, 8) from our laboratory. Isolated rat anococcygeus muscles were used for the potentiating activity assays of 2a-f in response to NE, which were evaluated from a shift in the concentrationresponse curves of NE. The ability of a compound to potentiate the action of NE was expressed as the activity ratio, which was determined from the antilogarithm of the difference between the pD 2 values for NE (negative logarithm of the molar concentration of the agonist producing 50% of the maximum response) in the presence and absence of the test compounds.
